Lenvatinib: Indications, Dosing, and Monitoring
Lenvatinib is a first-line oral multi-kinase inhibitor approved for advanced hepatocellular carcinoma (HCC) in patients with Child-Pugh class A liver function, radioiodine-refractory differentiated thyroid cancer (RAI-refractory DTC), and as combination therapy for renal cell carcinoma (RCC) and endometrial carcinoma (EC).
Primary Indications
Hepatocellular Carcinoma (HCC)
Lenvatinib is indicated as first-line monotherapy for patients with unresectable HCC who meet specific criteria 1, 2, 1:
- Child-Pugh class A liver function (preserved hepatic function)
- ECOG performance status 0-1
- Tumor occupying <50% of liver volume
- No main portal vein invasion or bile duct invasion
The REFLECT trial demonstrated non-inferior overall survival compared to sorafenib (13.6 vs 12.3 months; HR 0.92), with superior progression-free survival (7.4 vs 3.7 months) and objective response rate (18.8% vs 6.5%) 1. Lenvatinib serves as an alternative first-line option when atezolizumab plus bevacizumab is contraindicated 2.
Important caveat: Real-world studies suggest lenvatinib can be considered in patients beyond REFLECT criteria (Child-Pugh B, >50% liver involvement, main portal vein invasion, prior systemic therapy), but Child-Pugh B patients require meticulous monitoring for liver-related adverse events and have shorter overall survival 1.
Radioiodine-Refractory Differentiated Thyroid Cancer (RAI-refractory DTC)
Lenvatinib is approved for progressive, locally advanced or metastatic DTC refractory to radioactive iodine 3. It is the preferred first-line agent over sorafenib based on superior response rates (65% vs 12%), despite no head-to-head comparison 3. For second-line therapy after lenvatinib or sorafenib progression, cabozantinib is the recommended option 4, 3.
Other Indications
- Renal cell carcinoma: In combination with everolimus (following one prior anti-angiogenic therapy) 5
- Endometrial carcinoma: In combination with pembrolizumab (for advanced disease not MSI-H or pMMR) 5
Recommended Dosing Regimens
HCC Dosing (Weight-Based)
- Body weight ≥60 kg: 12 mg orally once daily
- Body weight <60 kg: 8 mg orally once daily
DTC Dosing
- 24 mg orally once daily (standard dose)
- A randomized trial demonstrated that the approved 24 mg dose achieved superior objective response rate (57.3%) compared to 18 mg (40.3%), supporting use of the full recommended dose 4
RCC and EC Dosing
- RCC: 18 mg once daily (with everolimus 5 mg once daily)
- EC: 20 mg once daily (with pembrolizumab 200 mg IV every 3 weeks)
Dose Modifications
Maintaining relative dose intensity >70% is critical for efficacy—patients with low dose intensity demonstrated significantly shorter progression-free survival 1. However, dose interruptions and reductions are frequently necessary:
- Grade 3 adverse events: Interrupt until recovery to grade 0-1, then resume at reduced dose
- Grade 4 adverse events: Discontinue or interrupt until recovery, then resume at reduced dose
- Dose reduction schedule:
- HCC (≥60 kg): 12 mg → 8 mg → 4 mg
- HCC (<60 kg): 8 mg → 4 mg → discontinue
- DTC: 24 mg → 20 mg → 14 mg → 10 mg
Critical point: Starting at reduced doses in fragile patients may be reasonable, but approximately 87% of patients started at reduced doses never escalate to the recommended label dose, potentially compromising efficacy 6. The data support starting at full dose with aggressive adverse event management rather than prophylactic dose reduction 1.
Monitoring Requirements
Pre-Treatment Evaluation
Cardiovascular assessment:
- Baseline blood pressure measurement
- ECG to assess QT interval
- Evaluate for history of cardiovascular disease, thromboembolism
- For bevacizumab combinations: Endoscopic evaluation and treatment of esophageal varices before initiating therapy 2
Laboratory baseline:
- Complete blood count
- Comprehensive metabolic panel (hepatic and renal function)
- Thyroid-stimulating hormone (TSH)
- Urinalysis with protein quantification
- Lipid panel
Pregnancy testing: Verify pregnancy status in females of reproductive potential 5
On-Treatment Monitoring
Hypertension (occurs in 42% of HCC patients)
- Patients with pre-existing hypertension: Monitor blood pressure daily initially
- All other patients: Monitor from 1 week after initiation, then weekly for first 2 months
- Management algorithm:
- SBP 135-159 mmHg or DBP 85-99 mmHg: Continue lenvatinib, initiate/intensify antihypertensive therapy
- SBP ≥160 mmHg or DBP ≥100 mmHg: Interrupt lenvatinib, initiate/intensify antihypertensives, resume at reduced dose once BP stable for ≥48 hours
- Hypertension predicts better prognosis, emphasizing importance of management rather than discontinuation 1
Proteinuria (occurs in 25% of HCC patients)
- Monitor urinalysis at baseline and regularly during treatment
- If dipstick shows 2+ or greater: Check random urine protein-to-creatinine ratio before proceeding to 24-hour urine collection
- Management:
- Grade 2 proteinuria: Continue lenvatinib, start ACE inhibitor or ARB
- 24-hour urinary protein ≥2 g: Interrupt lenvatinib
- Grade 3+ proteinuria: Interrupt until returns to 1+, then resume at reduced dose
- Chronic proteinuria: Discontinue lenvatinib
Thyroid Function
- Monitor TSH levels regularly (specific frequency not defined in guidelines, but typically every 4-8 weeks)
- TSH >10 mIU/L or >5 mIU/L on two separate occasions: Consider endocrinology consultation
- Hypothyroidism occurs in 16% of patients and is manageable with thyroid replacement
Hepatic Function (Critical in HCC patients)
- Monitor liver function tests (AST, ALT, bilirubin, albumin) regularly
- Child-Pugh B patients require more frequent monitoring due to higher risk of liver-related adverse events
- Assess for signs of hepatic decompensation
Other Key Monitoring
- Weight: Monitor at each visit; 10% loss from baseline warrants treatment interruption
- Diarrhea: Grade 1-2 managed with loperamide; persistent diarrhea requires 1-week interruption
- Hand-foot skin reaction (HFSR): Less common than sorafenib (27% vs 54%), but requires monitoring and symptomatic management
- Hemorrhagic events: Monitor for bleeding complications
- QT interval: Avoid coadministration with QT-prolonging medications 5
Adverse Event Management Strategy
The key principle is aggressive symptom management to maintain dose intensity rather than premature discontinuation, as patients who discontinued due to serious adverse events had significantly shorter overall survival 1.
Common Adverse Events (HCC population)
- Hypertension (42%)
- Diarrhea (39%)
- Anorexia (34%)
- Weight loss (31%)
- Fatigue (30%)
- Proteinuria (25%)
- HFSR (27%)
- Hypothyroidism (16%)
Predictors of Better Prognosis
Hypertension and HFSR are associated with improved outcomes, reinforcing the importance of managing these toxicities rather than discontinuing therapy 1.
Special Populations
Hepatic Impairment
- Mild (Child-Pugh A): No dose adjustment required
- Moderate (Child-Pugh B): Reduce dose (HCC: 8 mg if ≥60 kg, 4 mg if <60 kg; DTC: 14 mg; RCC: 10 mg)
- Severe (Child-Pugh C): Not studied; no systemic therapy options available 2
Renal Impairment
- CrCl 15-89 mL/min: No dose adjustment required
- End-stage renal disease: Not studied
Pregnancy and Contraception
- Contraindicated in pregnancy (can cause fetal harm)
- Females of reproductive potential must use effective contraception during treatment and for 30 days after last dose
- Discontinue breastfeeding during treatment and for 1 week after last dose
Clinical Pearls
- Dose intensity matters: Relative dose intensity >70% correlates with better progression-free survival 1
- Don't discontinue for manageable toxicity: Patients who stopped due to adverse events had worse survival 1
- Hypertension and HFSR are favorable prognostic markers: Aggressive management of these toxicities is essential 1
- Child-Pugh B patients can be treated but require intensive monitoring for hepatic decompensation 1
- Main portal vein invasion is a contraindication in HCC per FDA label, though real-world data suggest some patients may benefit with careful selection 2